{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:28:03Z","timestamp":1790962083610,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004381","name":"Western University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["385209"],"award-info":[{"award-number":["385209"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.cjco.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T03:22:51Z","timestamp":1631071371000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights"],"prefix":"10.1016","volume":"4","author":[{"given":"Markus","family":"Gulilat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racquel","family":"Jandoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivethika","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel G.","family":"Tirona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute I.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2021.09.002_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study","volume":"28","author":"Wolf","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.cjco.2021.09.002_bib2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2021.09.002_bib3","unstructured":"Heart and Stroke Foundation. Atrial fibrillation. Available at: https:\/\/www.heartandstroke.ca\/heart\/conditions\/atrial-fibrillation. Accessed 2020."},{"key":"10.1016\/j.cjco.2021.09.002_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1212\/WNL.0000000000000145","article-title":"Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Culebras","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.cjco.2021.09.002_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2021.09.002_bib6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2021.09.002_bib7","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.cjco.2021.09.002_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/phar.2350","article-title":"Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation","volume":"40","author":"Perreault","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cjco.2021.09.002_bib9","doi-asserted-by":"crossref","first-page":"e3522","DOI":"10.1136\/bmj.e3522","article-title":"Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study","volume":"344","author":"Friberg","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2021.09.002_bib10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2012.04853.x","article-title":"Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study","volume":"10","author":"Mikkelsen","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cjco.2021.09.002_bib11","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jama.2012.3490","article-title":"Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation","volume":"307","author":"Avgil Tsadok","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2021.09.002_bib12","doi-asserted-by":"crossref","first-page":"e014579","DOI":"10.1136\/bmjopen-2016-014579","article-title":"Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry","volume":"7","author":"Camm","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.cjco.2021.09.002_bib13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1160\/TH08-10-0635","article-title":"Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment","volume":"101","author":"Poli","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjco.2021.09.002_bib14","first-page":"3268","article-title":"Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial","volume":"36","author":"Vinereanu","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2021.09.002_bib15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1161\/STROKEAHA.114.005746","article-title":"Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study","volume":"45","author":"Lip","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.cjco.2021.09.002_bib16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2021.09.002_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.amjcard.2013.10.035","article-title":"Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants","volume":"113","author":"Pancholy","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2021.09.002_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1060028018771264","article-title":"Gender differences in efficacy and safety of direct oral anticoagulants in atrial fibrillation: systematic review and network meta-analysis","volume":"52","author":"Raccah","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjco.2021.09.002_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/psp4.12444","article-title":"Enhancing the quality of rivaroxaban exposure estimates using prothrombin time in the absence of pharmacokinetic sampling","volume":"8","author":"Solms","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cjco.2021.09.002_bib20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cjco.2021.09.002_bib21","unstructured":"Bristol-Myers Squibb Canada. Eliquis (apixaban) 2.5 mg and 5 mg product monograph. Available at: https:\/\/www.pfizer.ca\/eliquis-apixaban. Accessed October 7, 2019."},{"key":"10.1016\/j.cjco.2021.09.002_bib22","unstructured":"Bayer. Xarelto (rivaroxaban) 10 mg, 15 mg and 20 mg product monograph. Available at: https:\/\/www.bayer.ca\/omr\/online\/xarelto-pm-en.pdf. Accessed September 18, 2018."},{"key":"10.1016\/j.cjco.2021.09.002_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11239-019-01962-2","article-title":"Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care","volume":"49","author":"Gulilat","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.cjco.2021.09.002_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcph.5","article-title":"The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban\u2014an oral, direct Factor Xa inhibitor","volume":"53","author":"Kubitza","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cjco.2021.09.002_bib25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.kint.2016.10.017","article-title":"The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation","volume":"91","author":"Keskar","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjco.2021.09.002_bib26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.cjco.2021.09.002_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.cjco.2021.09.002_bib28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A\u00a0modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cjco.2021.09.002_bib29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun StatSimul Comput"},{"key":"10.1016\/j.cjco.2021.09.002_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIRCOUTCOMES.114.001398","article-title":"Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation","volume":"8","author":"Avgil Tsadok","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjco.2021.09.002_bib31","doi-asserted-by":"crossref","first-page":"e003418","DOI":"10.1161\/CIRCOUTCOMES.116.003418","article-title":"Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation","volume":"10","author":"Shantha","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjco.2021.09.002_bib32","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jamainternmed.2016.5451","article-title":"Lifelong gender gap in risk of incident myocardial infarction: the Tromso Study","volume":"176","author":"Albrektsen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjco.2021.09.002_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ehjcvp\/pvw042","article-title":"Gender differences in the effects of cardiovascular drugs","volume":"3","author":"Tamargo","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2021.09.002_bib34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.105.553438","article-title":"Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study","volume":"112","author":"Fang","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2021.09.002_bib35","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1093\/eurheartj\/ehl103","article-title":"Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials","volume":"27","author":"Gomberg-Maitland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2021.09.002_bib36","doi-asserted-by":"crossref","first-page":"e012564","DOI":"10.1136\/bmjopen-2016-012564","article-title":"Narrowing mortality gap between men and women over two decades: a registry-based study in Ontario, Canada","volume":"6","author":"Rosella","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.cjco.2021.09.002_bib37","doi-asserted-by":"crossref","first-page":"h7013","DOI":"10.1136\/bmj.h7013","article-title":"Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies","volume":"532","author":"Emdin","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2021.09.002_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.clpt.6100226","article-title":"The current state of knowledge on age, sex, and their interactions on clinical pharmacology","volume":"82","author":"Schwartz","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X21002353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X21002353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:06:50Z","timestamp":1762902410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X21002353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2589790X21002353"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2021.09.002","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}